Introduction to the reviews on neuropeptide Y.
Neuropeptide Y (NPY) was first reported as an abundant peptide in brain tissue in 1982. Shortly thereafter, NPY was found to be a member of a peptide family consisting of the endocrine peptides pancreatic polypeptide (PP) and peptide YY (PYY). These peptides exert most of their biological effects through five G-protein coupled receptors termed Y1, Y2, Y4, Y5 and y6 that mediate either inhibition adenylate cyclase or increases in intracellular calcium. Since the discovery of NPY, a robust a body of literature has developed around the potential functions of this peptide. While initial findings identified NPY is an important contributor to the regulation of feeding, body weight and blood pressure, more recent work as revealed more subtle functions of this peptide and its potential role in affective disorders, bone formation and cravings. The accompanying twelve reviews detail important developments in our understanding of the functional role of NPY.
Gehlert
D R
DR
Lilly Research Laboratories, Neuroscience Division, Eli Lilly and Company, Lilly Corporate Center, Mail Code 0510, Indianapolis, IN 46285, USA. gehlert_donald_r@lilly.com
D000818:Animals; D001921:Brain / Q000378:metabolism*; D006801:Humans; D009478:Neuropeptide Y / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000235:genetics / Q000378:metabolism
D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y